4Shyangdan D,Clar C,Ghouri N,et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic re- view. Health Technol Assess,2011,15(38 ) : 100-110.
8Martin CK,Redman LM,Zhang J,et al. Lorcaserin,a 5-HT (2C) receptor agonist,reduces body weight by decreasing ener- gy intake without influencing energy expenditure. J Clin En- doerinol Metab,2011,96(3) : 837-845.
9Fidler MC,Sanchez M,Raether B,et al. A one-year random- ized trial of lorcasefin for weight loss in obese and overweight adults:the BLOSSOM trial. J Clin Endocrinol Metab,2011,96 ( 10) : 3067-3077.
10O'Neil PM,Smith SR,Weissman NJ,et al. Randomized place- bo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus:tbe BLOOM-DM study. Obesity (Silver Spring), 2012,20(7): 1426-1436.
1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1511
2Pascale A, Pais R, Ratziu V. An overview of non- alcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis ,2010, 19:415-423 [PMID: 21188334].
3Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepa- tol ,2013, 28 Suppl 1:11-17 [PMID: 23855290 DOI: 10.1111/jgh.12036].
4Fabbrini E, Sullivan S, Klein S. Obesity and nonalco- holic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology ,2010, 51:679-689 [PMID: 20041406 DOI: 10.1002/hep.23280].
5Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver dis- ease in obese Taiwan Residents children. J Pediatr ,2011, 158:740-744 [PMID: 21168155 DOI: 10.1016/ j.jpeds.2010.11.016].
6Lin YC, Chang PF, Chang MH, Ni YH. Genetic vari- ants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr ,2014, 99:869-874 [PMID: 24477042 DOI: 10.3945/ajcn.113.079749].
7Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor- coactivator-la gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr ,2013, 97:326-331 [PMID: 23269818 DOI: 10.3945/ajcn.112.046417].
8Feldstein AE, Charatcharoenwitthaya P, Treepraser- tsuk S, Benson JT, Enders FB, Angulo P. The natu- ral history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut ,2009, 58:1538-1544 [PMID: 19625277 DOh 10.1136/ gut.2008.171280].
9Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curt Mol Med ,2009, 9: 299-314 [PMID: 19355912 DOI: 10.2174/1566524097 87847191].
10Day CP. Non-alcoholic fatty liver disease: a mas- sive problem. Clin Med ,2011, 11:176-178 [PMID: 21526706 DOI: 10.7861/clinmedicine.11-2-176].
